NCT06088888View on ClinicalTrials.gov

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

March 30, 2027

Study Completion Date

June 30, 2027

Conditions
Chronic Myelogenous Leukemia
Interventions
DRUG

TGRX-678

Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.

Trial Locations (2)

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

98102

RECRUITING

Fred Hutchinson Cancer Center, Seattle

All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

Shenzhen TargetRx, Inc.

INDUSTRY